O-Vanillin Attenuates the TLR2 Mediated Tumor-Promoting Phenotype of Microglia.
Animals
Astrocytes
/ metabolism
Benzaldehydes
/ pharmacology
Biomarkers
Cell Line, Tumor
Cell Proliferation
Cytokines
/ genetics
Disease Susceptibility
Gene Expression Regulation
Glioma
/ etiology
Humans
Matrix Metalloproteinase 9
/ genetics
Microglia
/ drug effects
Neoplasms
/ etiology
Signal Transduction
Toll-Like Receptor 2
/ metabolism
TLR2
glioma
microglia
therapy
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
17
03
2020
revised:
19
04
2020
accepted:
21
04
2020
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
26
1
2021
Statut:
epublish
Résumé
Malignant gliomas are primary brain tumors with poor prognoses. These tumors are infiltrated by brain intrinsic microglia and peripheral monocytes which promote glioma cell invasion. In our previous studies, we discovered that the activation of Toll-like receptor 2 (TLR2) on microglia/brain macrophages converts them into a protumorigenic phenotype through the induction of matrix metalloproteinases (MMP) 9 and 14. In the present study, we used in vitro and in situ microglia-glioma interaction experimental models to test the impact of a novel inhibitor of TLR 2, ortho vanillin (O-Vanillin) to block TLR2 mediated microglia protumorigenic phenotype. We demonstrate that O-Vanillin inhibits the TLR2 mediated upregulation of
Identifiants
pubmed: 32331440
pii: ijms21082959
doi: 10.3390/ijms21082959
pmc: PMC7215774
pii:
doi:
Substances chimiques
Benzaldehydes
0
Biomarkers
0
Cytokines
0
Toll-Like Receptor 2
0
2-vanillin
008LR748FI
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Monika Kutzner Stiftung
ID : KS 3210032
Références
J Neuroinflammation. 2013 Jul 17;10:85
pubmed: 23866312
J Agric Food Chem. 2009 Apr 22;57(8):3055-63
pubmed: 19368348
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12530-5
pubmed: 19617536
J Neurosci Res. 1994 Feb 1;37(2):182-96
pubmed: 8151727
Eur J Pharm Sci. 2005 May;25(1):57-65
pubmed: 15854801
Glia. 2013 Jul;61(7):1178-90
pubmed: 23650109
J Cell Physiol. 2011 Jun;226(6):1573-82
pubmed: 20945380
Neuro Oncol. 2015 Feb;17(2):200-10
pubmed: 25452390
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
PLoS One. 2015 Feb 06;10(2):e0116644
pubmed: 25658639
BMC Mol Biol. 2009 Mar 03;10:17
pubmed: 19257903
J Neuropathol Exp Neurol. 2005 Sep;64(9):754-62
pubmed: 16141784
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5455-60
pubmed: 25870276
Anticancer Res. 2016 Nov;36(11):5743-5750
pubmed: 27793895
Nature. 2009 Jan 1;457(7225):102-6
pubmed: 19122641
Neuro Oncol. 2013 Nov;15(11):1457-68
pubmed: 24014382
Gynecol Oncol. 2014 Nov;135(2):359-63
pubmed: 25135000
Int J Cancer. 2014 Dec 1;135(11):2569-78
pubmed: 24752463
J Neurosci Res. 1996 Jul 15;45(2):161-73
pubmed: 8843033
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
Cancer Immunol Immunother. 2016 Oct;65(10):1261-8
pubmed: 27344341
Inflamm Res. 2017 Oct;66(10):843-853
pubmed: 28593434
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Neurochem Res. 2016 Aug;41(8):1899-910
pubmed: 27038927
Microsc Res Tech. 2001 Jul 15;54(2):106-13
pubmed: 11455617
Neuro Oncol. 2012 Aug;14(8):958-78
pubmed: 22573310